Published in Mult Scler on August 23, 2012
Simvastatin in Secondary Progressive Multiple Sclerosis (MS-OPT) | NCT03896217
MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies. J Exp Med (2013) 1.88
Reduced gamma-aminobutyric acid concentration is associated with physical disability in progressive multiple sclerosis. Brain (2015) 1.46
Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity. Neurology (2014) 1.21
Inefficient clearance of myelin debris by microglia impairs remyelinating processes. J Exp Med (2015) 1.01
Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis. Neurotherapeutics (2016) 0.88
Evidence for early neurodegeneration in the cervical cord of patients with primary progressive multiple sclerosis. Brain (2015) 0.82
Regression to the mean and predictors of MRI disease activity in RRMS placebo cohorts--is there a place for baseline-to-treatment studies in MS? PLoS One (2015) 0.82
Validating predictors of disease progression in a large cohort of primary-progressive multiple sclerosis based on a systematic literature review. PLoS One (2014) 0.82
B Cells Are Multifunctional Players in Multiple Sclerosis Pathogenesis: Insights from Therapeutic Interventions. Front Immunol (2015) 0.81
Contribution of genome-wide association studies to scientific research: a pragmatic approach to evaluate their impact. PLoS One (2013) 0.81
The role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosis. Prog Neurobiol (2015) 0.79
Microglia Ontology and Signaling. Front Cell Dev Biol (2016) 0.77
Gene expression changes underlying cortical pathology: clues to understanding neurological disability in multiple sclerosis. Mult Scler (2013) 0.76
Beta-interferon exposure and onset of secondary progressive multiple sclerosis. Eur J Neurol (2015) 0.76
Multiple Sclerosis International Federation: stimulating international cooperation in research. Neurology (2013) 0.75
Imag(in)ing multiple sclerosis: Time to take better pictures. J Neuroimmunol (2016) 0.75
Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis. Contemp Clin Trials (2016) 0.75
Comparative utility of disability progression measures in PPMS: Analysis of the PROMiSe data set. Neurol Neuroimmunol Neuroinflamm (2017) 0.75
Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology (1983) 40.64
Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes (2006) 26.32
Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med (2007) 17.06
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology (1996) 10.26
Predicting new molecular targets for known drugs. Nature (2009) 9.71
Drug target identification using side-effect similarity. Science (2008) 9.24
Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet (2003) 4.27
Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet (2009) 3.51
Evidence for polygenic susceptibility to multiple sclerosis--the shape of things to come. Am J Hum Genet (2010) 2.64
Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol (2009) 2.43
Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol (2010) 2.40
Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group. Neurology (1990) 2.24
Anxiety disorders and their clinical correlates in multiple sclerosis patients. Mult Scler (2007) 2.19
Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann Neurol (2009) 2.18
Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Neurol (2010) 2.03
Cortical adaptation in patients with MS: a cross-sectional functional MRI study of disease phenotypes. Lancet Neurol (2005) 2.01
Point-and-click cursor control with an intracortical neural interface system by humans with tetraplegia. IEEE Trans Neural Syst Rehabil Eng (2011) 2.00
Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Ann Neurol (1997) 1.72
Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis. J Consult Clin Psychol (2001) 1.66
Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology (2009) 1.59
Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects. Lancet Neurol (2012) 1.50
The relevance of animal models in multiple sclerosis research. Pathophysiology (2011) 1.40
Pharmacological management of symptoms in multiple sclerosis: current approaches and future directions. Lancet Neurol (2010) 1.29
Brain tissue sodium concentration in multiple sclerosis: a sodium imaging study at 3 tesla. Brain (2010) 1.27
Experimental models of multiple sclerosis. Curr Opin Neurol (2011) 1.17
Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity? Acta Neuropathol (2012) 1.13
Chronic progressive multiple sclerosis - pathogenesis of neurodegeneration and therapeutic strategies. Curr Neuropharmacol (2010) 1.10
Energy failure in multiple sclerosis and its investigation using MR techniques. J Neurol (2011) 1.06
Functional brain reorganization in multiple sclerosis: evidence from fMRI studies. J Neuroimaging (2006) 1.04
Models of autoimmune demyelination in the central nervous system: on the way to translational medicine. Exp Transl Stroke Med (2009) 1.03
Measuring myelin repair and axonal loss with diffusion tensor imaging. AJNR Am J Neuroradiol (2010) 1.03
CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis. Neurology (2004) 1.03
CytoSolve: A Scalable Computational Method for Dynamic Integration of Multiple Molecular Pathway Models. Cell Mol Bioeng (2010) 1.02
Autoimmune tolerance eliminates relapses but fails to halt progression in a model of multiple sclerosis. J Neuroimmunol (2005) 0.98
Training-dependent plasticity in patients with multiple sclerosis. Brain (2004) 0.94
Quality of life in multiple sclerosis: determinants, measurement, and use in clinical practice. Curr Neurol Neurosci Rep (2010) 0.94
A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis. Mult Scler (2010) 0.90
Efficacy of paroxetine in treating major depressive disorder in persons with multiple sclerosis. Gen Hosp Psychiatry (2007) 0.89
Experimental in vivo and in vitro models of multiple sclerosis: EAE and beyond. Mult Scler Relat Disord (2011) 0.86
Relation between functional brain imaging, cognitive impairment and cognitive rehabilitation in patients with multiple sclerosis. J Neurol (2007) 0.84
Nonprofit disease groups earmark grants for drug repositioning. Nat Med (2011) 0.83
Towards molecular imaging of multiple sclerosis. Mult Scler (2011) 0.82
Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data. Neuroimage (2006) 23.57
Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet (2008) 15.43
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med (2010) 13.82
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
Design of a novel globular protein fold with atomic-level accuracy. Science (2003) 13.06
Protein structure prediction using Rosetta. Methods Enzymol (2004) 12.05
Predicting protein structures with a multiplayer online game. Nature (2010) 9.95
EMBL Nucleotide Sequence Database in 2006. Nucleic Acids Res (2006) 9.72
Toward high-resolution de novo structure prediction for small proteins. Science (2005) 9.18
Protein-protein docking with simultaneous optimization of rigid-body displacement and side-chain conformations. J Mol Biol (2003) 8.35
Macromolecular modeling with rosetta. Annu Rev Biochem (2008) 8.32
Kemp elimination catalysts by computational enzyme design. Nature (2008) 8.19
Evaluation of structural and evolutionary contributions to deleterious mutation prediction. J Mol Biol (2002) 7.79
High-resolution structure prediction and the crystallographic phase problem. Nature (2007) 7.67
De novo computational design of retro-aldol enzymes. Science (2008) 7.62
Protein structure prediction and analysis using the Robetta server. Nucleic Acids Res (2004) 7.39
ROSETTA3: an object-oriented software suite for the simulation and design of macromolecules. Methods Enzymol (2011) 7.33
The EMBL Nucleotide Sequence Database. Nucleic Acids Res (2005) 7.18
Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med (2006) 7.18
The genome sequence of the rice blast fungus Magnaporthe grisea. Nature (2005) 6.95
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med (2006) 6.90
Consistent blind protein structure generation from NMR chemical shift data. Proc Natl Acad Sci U S A (2008) 6.76
The EMBL Nucleotide Sequence Database. Nucleic Acids Res (2004) 6.72
A simple physical model for binding energy hot spots in protein-protein complexes. Proc Natl Acad Sci U S A (2002) 6.18
Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet (2009) 6.04
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet (2013) 5.58
Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. Nature (2003) 5.31
The UniProt-GO Annotation database in 2011. Nucleic Acids Res (2011) 5.19
EMBL Nucleotide Sequence Database: developments in 2005. Nucleic Acids Res (2006) 5.13
Crystal structure of a monomeric retroviral protease solved by protein folding game players. Nat Struct Mol Biol (2011) 5.02
Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med (2011) 4.93
Towards robust regional estimates of CO2 sources and sinks using atmospheric transport models. Nature (2002) 4.71
An orientation-dependent hydrogen bonding potential improves prediction of specificity and structure for proteins and protein-protein complexes. J Mol Biol (2003) 4.63
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet (2013) 4.62
Effects of Bacille Calmette-Guerin after the first demyelinating event in the CNS. Neurology (2013) 4.60
Assigning function to yeast proteins by integration of technologies. Mol Cell (2003) 4.58
Ca2+ indicators based on computationally redesigned calmodulin-peptide pairs. Chem Biol (2006) 4.52
Computational design of proteins targeting the conserved stem region of influenza hemagglutinin. Science (2011) 4.42
Protein-protein docking with backbone flexibility. J Mol Biol (2007) 4.32
Computational design of an enzyme catalyst for a stereoselective bimolecular Diels-Alder reaction. Science (2010) 4.32
Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet (2003) 4.27
Improving physical realism, stereochemistry, and side-chain accuracy in homology modeling: Four approaches that performed well in CASP8. Proteins (2009) 4.27
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med (2010) 4.08
Computational redesign of endonuclease DNA binding and cleavage specificity. Nature (2006) 4.06
Quantitative reactivity profiling predicts functional cysteines in proteomes. Nature (2010) 4.04
Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat Genet (2009) 3.94
Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health (2011) 3.88
Automated de novo prediction of native-like RNA tertiary structures. Proc Natl Acad Sci U S A (2007) 3.87
Priorities for nucleotide trace, sequence and annotation data capture at the Ensembl Trace Archive and the EMBL Nucleotide Sequence Database. Nucleic Acids Res (2007) 3.84
A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med (2002) 3.74
Algorithm discovery by protein folding game players. Proc Natl Acad Sci U S A (2011) 3.74
Computational redesign of protein-protein interaction specificity. Nat Struct Mol Biol (2004) 3.66
Modeling structurally variable regions in homologous proteins with rosetta. Proteins (2004) 3.64
Structure prediction for CASP8 with all-atom refinement using Rosetta. Proteins (2009) 3.64
ROSETTALIGAND: protein-small molecule docking with full side-chain flexibility. Proteins (2006) 3.60
Rational HIV immunogen design to target specific germline B cell receptors. Science (2013) 3.55
Neurosphere-derived multipotent precursors promote neuroprotection by an immunomodulatory mechanism. Nature (2005) 3.53
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol (2011) 3.52
High-resolution mapping of protein sequence-function relationships. Nat Methods (2010) 3.47
Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature (2006) 3.45
Computational alanine scanning of protein-protein interfaces. Sci STKE (2004) 3.41
Automated prediction of CASP-5 structures using the Robetta server. Proteins (2003) 3.41
New algorithms and an in silico benchmark for computational enzyme design. Protein Sci (2006) 3.40
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol (2009) 3.37
Distinct roles of GIGANTEA in promoting flowering and regulating circadian rhythms in Arabidopsis. Plant Cell (2005) 3.33
Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial. Clin Infect Dis (2009) 3.32
Inflammation in neurodegenerative diseases. Immunology (2010) 3.22
An engineered microbial platform for direct biofuel production from brown macroalgae. Science (2012) 3.20
Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol (2011) 3.16
A large scale test of computational protein design: folding and stability of nine completely redesigned globular proteins. J Mol Biol (2003) 3.08
Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet (2011) 3.07
Atomic accuracy in predicting and designing noncanonical RNA structure. Nat Methods (2010) 3.07
Progress in modeling of protein structures and interactions. Science (2005) 3.05
Functional-anatomical validation and individual variation of diffusion tractography-based segmentation of the human thalamus. Cereb Cortex (2004) 3.03
Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc Natl Acad Sci U S A (2009) 3.01
Structure prediction for CASP7 targets using extensive all-atom refinement with Rosetta@home. Proteins (2007) 3.01
NMR structure determination for larger proteins using backbone-only data. Science (2010) 3.00
Response to self antigen imprints regulatory memory in tissues. Nature (2011) 2.96
Refinement of protein structures into low-resolution density maps using rosetta. J Mol Biol (2009) 2.94
The 3D profile method for identifying fibril-forming segments of proteins. Proc Natl Acad Sci U S A (2006) 2.88
Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med (2007) 2.88
De novo prediction of three-dimensional structures for major protein families. J Mol Biol (2002) 2.88
RosettaLigand docking with full ligand and receptor flexibility. J Mol Biol (2008) 2.86
Voltage sensor conformations in the open and closed states in ROSETTA structural models of K(+) channels. Proc Natl Acad Sci U S A (2006) 2.81
Multipass membrane protein structure prediction using Rosetta. Proteins (2006) 2.79
Computational thermostabilization of an enzyme. Science (2005) 2.79
Rosetta predictions in CASP5: successes, failures, and prospects for complete automation. Proteins (2003) 2.77
Transcriptional regulation of biomass-degrading enzymes in the filamentous fungus Trichoderma reesei. J Biol Chem (2003) 2.77
Improved molecular replacement by density- and energy-guided protein structure optimization. Nature (2011) 2.74
Improved side-chain modeling for protein-protein docking. Protein Sci (2005) 2.72
Close agreement between the orientation dependence of hydrogen bonds observed in protein structures and quantum mechanical calculations. Proc Natl Acad Sci U S A (2004) 2.71
Elicitation of structure-specific antibodies by epitope scaffolds. Proc Natl Acad Sci U S A (2010) 2.68
Role of conformational sampling in computing mutation-induced changes in protein structure and stability. Proteins (2010) 2.56
CASD-NMR: critical assessment of automated structure determination by NMR. Nat Methods (2009) 2.50
A vast repertoire of Dscam binding specificities arises from modular interactions of variable Ig domains. Cell (2007) 2.50
Principles for designing ideal protein structures. Nature (2012) 2.50
Solution structure of a minor and transiently formed state of a T4 lysozyme mutant. Nature (2011) 2.49
Physically realistic homology models built with ROSETTA can be more accurate than their templates. Proc Natl Acad Sci U S A (2006) 2.47